• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    FDA OKs World's First Single-Use Duodenoscope

    Dr. Stephen Hahn Confirmed as New FDA Leader

    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy

    MedStar Health and Cleveland Clinic Innovations Awarded Grant

    3M to Sell Drug Delivery Business for $650M
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Adding Fabrication Capabilities: Additive Manufacturing for Production Parts

    Delivering the Goods: The Evolving World of Combination Products

    Anxious Undertones: The 2019 Year in Review

    From Art to Science: The Changing Face of Extrusion

    Exact Science: A Micromolding Roundtable
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    From Genome Sequencing to the World’s First Portable MRI

    An Update on Digital Health

    ‘If You’re Reading This, You Need to Be at This Meeting’

    Five Steps for Succeeding Globally in Medtech

    Unlocking Market Doors with Real-World Evidence
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    RJG Inc.

    Zeus

    Halkey-Roberts Corporation

    NN Life Sciences/Paragon Medical

    Eurofins Medical Device Testing
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    EU's MDR: Irresistible Force Meets Immovable Object

    Ladies First: An Examination of the Women's Health Device Industry

    Localizing Medical Devices

    Sounding Board: Looking Back at 2019 and Gazing at 2020

    Understanding Key Processes for Mixing APIs with Silicone
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Accumold

    Fusion Biotec Inc.

    GS Plastic Optics

    Marox Corporation

    FUTEK Advanced Sensor Technology Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Breaking News

    23andMe Granted First FDA Authorization for Direct-to-Consumer Cancer Risk Genetic Test

    Customers can now receive, without a prescription, information on three genetic variants associated with breast cancer.

    23andMe Granted First FDA Authorization for Direct-to-Consumer Cancer Risk Genetic Test
    Related CONTENT
    • 'Risk-on-a-Chip' Simulates Conditions for Breast Cancer Formation
    • FDA Grants ExThera Medical’s Seraph 100 Blood Filter Expedited Access Pathway Designation
    • GE Healthcare Launches Mammography System That Allows Patients to Control Their Compression
    • First Patient Enrolled in Clinical Project Comparing SoftVue and Mammography in Dense Breast Tissue
    • 'Labyrinth' Chip Monitors Aggressive Cancer Stem Cells
    PR Newswire03.07.18
    23andMe Inc., the personal genetics company, received the first-ever FDA authorization for a direct-to-consumer genetic test for cancer risk. The authorization allows 23andMe to provide customers, without a prescription, information on three genetic variants found on the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian and prostate cancer.
     
    "Being the first and only direct-to-consumer genetics company to receive FDA authorization to test for cancer risk without a prescription is a major milestone for 23andMe and for the consumer," said Anne Wojcicki, 23andMe CEO and co-founder. "We believe it's important for consumers to have direct and affordable access to this potentially life-saving information. We will continue pioneering a path for greater access to health information, and promoting a more consumer-driven, preventative approach to healthcare."
     
    23andMe will report on three variants in the BRCA1 and BRCA2 genes associated with a significantly higher risk of breast and ovarian cancer in women, and breast cancer in men. The variants may also be associated with an increased risk for certain other cancers. These variants are most prevalent in those of Ashkenazi Jewish descent, and have been observed at much lower rates in other ethnicities. About 1 in 40 individuals of Ashkenazi Jewish descent has one of these three variants. Women with one of these variants have a 45-85 percent chance of developing breast cancer by age 70.
     
    "This authorization is incredibly valuable for those who might not be aware of their Ashkenazi Jewish descent or aren't familiar with their family history of cancer," said Wojcicki. "But it's important to understand that the majority of cancer is not hereditary, our test does not account for all genetic variants that can cause a higher risk of cancer, and people should continue with their recommended cancer screenings."
     
    New and existing 23andMe Health + Ancestry Service customers that were genotyped on the company's most recent platforms will have access to this report in the coming weeks. As with select other Genetic Health Risk reports, customers must specifically choose for themselves if and when they want to receive this information. The report also includes an education module to ensure customers are fully informed on what they can learn from this report and how to use the results.
     
    The 23andMe Personal Genome Service submission for the BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report was extensively evaluated through the FDA de novo classification pathway, a regulatory process enabling classification and authorization for novel moderate-risk medical devices (FDA authorization # DEN170046). As part of the review process in order to establish safety and effectiveness for this authorization, 23andMe demonstrated a high level of accuracy (greater than 99 percent concordance to Sanger sequencing) and precision (demonstrated by studies yielding greater than 99 percent reproducibility and repeatability).
     
    The 23andMe BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report utilizes the same informational concepts previously demonstrated in studies submitted to the FDA for its Genetic Health Risk reports which were shown to have 90 percent or greater overall user comprehension in a demographically diverse population study.
     
    Current clinical guidelines for genetic risk evaluation are based primarily on personal and/or family history of certain cancers. However, a perspective by Mary Claire-King, Ph.D. (who received the Lasker award in 2014 in recognition of her pioneering discovery of the BRCA1 gene) published in The Journal of the American Medical Association has argued for broader access, citing a study where "50 percent of families found to harbor BRCA1 or BRCA2 mutations had no history of breast or ovarian cancer that would have triggered clinical attention." (https://jamanetwork.com/journals/jama/fullarticle/1902783)
     
    Consistent with those previous findings, 23andMe found that of those BRCA carriers who gave family medical history, about half reported no history of cancer in first-degree relatives. 23andMe has also observed that many of its customers for whom Ashkenazi Jewish ancestry was detected, did not self report any Jewish ancestry. These individuals might fall outside the guidelines of clinical testing.
     
    With this authorization, 23andMe continues to pioneer consumer access to genetic information, and remains the only company able to offer genetic health risk reports without a prescription. This authorization is the third de novo authorization granted by the FDA to 23andMe. In February 2015, 23andMe was granted authorization by the FDA to market the first direct-to-consumer genetic test for Bloom Syndrome under the de novo pathway which has since enabled the company to bring 40+ carrier status reports directly to customers. These reports convey risk for diseases that may be passed to offspring. In April 2017, 23andMe was granted authorization by the FDA to market the first direct-to-consumer genetic health risk reports, to date the company has launched 9 reports for a variety of genetic health risks.
    Related Searches
    • prostate cancer
    • mutations
    • company
    • testing
    Related Knowledge Center
    • Diagnostics
    Suggested For You
    FDA Commissioner Comments on Essure Birth Control Implant FDA Commissioner Comments on Essure Birth Control Implant's Ongoing Post-Market Review
    FDA Expands Heart Valve Approval to Include Size for Newborn Patients FDA Expands Heart Valve Approval to Include Size for Newborn Patients
    Mike on Medtech: Quality vs. Regulatory Mike on Medtech: Quality vs. Regulatory
    Brain Implant for Some Blind People Shows Benefits of FDA’s Breakthrough Device Program Brain Implant for Some Blind People Shows Benefits of FDA’s Breakthrough Device Program
    Quality Nightmares #35: The Rejection Quality Nightmares #35: The Rejection
    Quality Nightmares #34: The FDA Auditor Quality Nightmares #34: The FDA Auditor
    At-Home Device Helps Women Detect Lesions in Breast Tissue At-Home Device Helps Women Detect Lesions in Breast Tissue
    Mike on Medtech: The Mike on Medtech: The 'New' Alternative 510k
    FDA Warns BD About Blood Collection Tubes Used in Lead Testing Kit FDA Warns BD About Blood Collection Tubes Used in Lead Testing Kit
    FDA Issues Class I Recall for Sterilmed Reprocessed Agilis Steerable Introducer Sheath FDA Issues Class I Recall for Sterilmed Reprocessed Agilis Steerable Introducer Sheath
    Mike on Medtech: Regulatory Approval Pathway for Biomaterials Mike on Medtech: Regulatory Approval Pathway for Biomaterials
    Opto-Acoustic Breast Imaging System Offers Critical Tumor Subtype Diagnostic & Prognostic Info Opto-Acoustic Breast Imaging System Offers Critical Tumor Subtype Diagnostic & Prognostic Info
    New Blood Test Developed to Diagnose Ovarian Cancer New Blood Test Developed to Diagnose Ovarian Cancer
    New Epigenetic Blood Test May Diagnose Breast Cancer New Epigenetic Blood Test May Diagnose Breast Cancer
     TransMed7 LLC Announces Breast Health Chair Appointment TransMed7 LLC Announces Breast Health Chair Appointment

    Related Breaking News

    • Diagnostics
      FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy

      FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy

      PerkinElmer's test measures dried blood samples collected from the prick of a newborn’s heel 24 to 48 hours after birth.
      U.S. Food and Drug Administration 12.13.19

    • Diagnostics
      Lens-Free Microendoscope Generates High Quality Images

      Lens-Free Microendoscope Generates High Quality Images

      It also doesn't require movement to focus on objects at different depths.
      Johns Hopkins University 12.10.19

    • Diagnostics
      NeuMoDx Molecular and Sentinel Diagnostics Partner

      NeuMoDx Molecular and Sentinel Diagnostics Partner

      Work together to develop multiple new assays for the NeuMoDx Molecular Systems.
      NeuMoDx Molecular 12.10.19


    • Diagnostics
      Companies Partner to Develop Instrument-Free Molecular Diagnostic Tests

      Companies Partner to Develop Instrument-Free Molecular Diagnostic Tests

      Collaboration facilitated by the Bill & Melinda Gates Foundation through an expansion of an existing grant.
      Business Wire 12.09.19

    • Diagnostics
      BWXT to Produce Medical Radioisotope Germanium-68 to Meet Rise in Demand

      BWXT to Produce Medical Radioisotope Germanium-68 to Meet Rise in Demand

      Company is in the process of scaling up its capacity to move into full production in 2020.
      Business Wire 12.09.19

    • Diagnostics
      FDA Clears Molecular Screening Test for Detection of Antibiotic-Resistant Bacteria

      FDA Clears Molecular Screening Test for Detection of Antibiotic-Resistant Bacteria

      BD MAX Check-Points CPO assay can identify the five most common carbapenemase genes from patients.
      BD 12.09.19


    • Diagnostics
      FDA OKs Roche

      FDA OKs Roche's Nasal Swab MRSA Test

      The cobas vivoDx MRSA test can detect the bacteria in as little as five hours.
      U.S. Food and Drug Administration 12.06.19

    • Diagnostics | Digital Health | Software & IT
      Philips & Paige to Deliver Clinical-Grade AI Applications to Pathology Labs

      Philips & Paige to Deliver Clinical-Grade AI Applications to Pathology Labs

      Aim is to help pathologists identify, quantify, and characterize cancer in tissue samples and make precise diagnoses more efficiently.
      Philips 12.05.19

    • Diagnostics | Neurological
      Eye Test for Parkinson

      Eye Test for Parkinson's Gains Breakthrough Designation

      The RightEye Vision System identifies ocular tremors that may help to detect the disease at an earlier stage.
      PR Newswire 12.05.19


    • Diagnostics | Neurological
      RSNA News: MaxQ AI Expands Partnership with GE

      RSNA News: MaxQ AI Expands Partnership with GE

      MaxQ AI’s ACCIPIO ICH and Stroke platform will be integrated into GE Healthcare’s PACS solution.
      MaxQ Al 12.04.19

    • Diagnostics | Neurological
      RSNA News: MaxQ AI to Offer Accipio Applications on Blackford Platform

      RSNA News: MaxQ AI to Offer Accipio Applications on Blackford Platform

      Represents cost savings and increased quality of care.
      MaxQ AI 12.04.19

    • Diagnostics
      Hyperfine Introduces World’s First Point-of-Care MRI System

      Hyperfine Introduces World’s First Point-of-Care MRI System

      The company's portable MRI is 20 times less costly, 35 times lower power, and 10 times lighter than the most popular current MRI machines.
      Business Wire 12.04.19

    • Diagnostics | Neurological
       RSNA News: MaxQ AI’s Software Integrated with Philips

      RSNA News: MaxQ AI’s Software Integrated with Philips' Tech

      The company’s Accipio Intracranial Hemorrhage and stroke software will be added to Philips’ CT systems
      MaxQ 12.04.19

    • Diagnostics
      RSNA News: Philips Transitions to the Circular Economy

      RSNA News: Philips Transitions to the Circular Economy

      Collecting and repurposing all the large medical systems equipment.
      Philips 12.03.19

    • Diagnostics
      RSIP Vision Introduces AI-Based Multiplex IF Image Analysis Solution

      RSIP Vision Introduces AI-Based Multiplex IF Image Analysis Solution

      Provides precise results in tissue diagnosis.
      PRNewswire 12.03.19


    Breaking News
    • FDA OKs World's First Single-Use Duodenoscope
    • Dr. Stephen Hahn Confirmed as New FDA Leader
    • FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    • MedStar Health and Cleveland Clinic Innovations Awarded Grant
    • 3M to Sell Drug Delivery Business for $650M
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • Adding Fabrication Capabilities: Additive Manufacturing for Production Parts
    • Delivering the Goods: The Evolving World of Combination Products
    • Anxious Undertones: The 2019 Year in Review
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Arkema: Bostik Acquires Danish Company LIP
    Axalta Adds New Epoxy Primer to Tufcote Liquid Industrial Coatings Portfolio
    Chromaflo Technologies Promotes Sergio Duenas to Country Manager of Mexico
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs World's First Single-Use Duodenoscope
    Dr. Stephen Hahn Confirmed as New FDA Leader
    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness
    Amgen Selects Location For R&D Facility
    Arctoris Opens Oxford R&D Facility
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Prada & L’Oréal Sign Long-Term Licensing Deal
    Happi

    Latest Breaking News From Happi

    Cosmetic Assessments Revealed at CIR Panel
    T-Boz Launches CBD Line
    DRF and Flowerkist Develop CBD Range
    Ink World

    Latest Breaking News From Ink World

    Ripon Printers Adds Ricoh Pro C9210
    LogoJet Opens Bogota, Colombia Office
    Canon Solutions America Powers University of Notre Dame Athletics' Printing Capabilities
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    GSE products provide quality assurance for Pharmalabel
    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    DuPont to Acquire Osmosis Specialist
    Nice-Pak to Expand in Indiana
    Hospeco Launches Compact Fem Hy Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    TriMed Closes Out FDA Warning Letter
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    3D Printing Materials Market to Grow at 23.9% CAGR Through 2025: GVR
    Kyocera, TactoTek Collaborate on Injection Molded Structural Electronics Solutions
    Toray Opens R&D Innovation Center for the Future

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.